摘要
目的:探讨聚乙二醇干扰素α-2b注射液联合恩替卡韦应用于e抗原阳性慢性乙型肝炎(CHB)患者的临床疗效。方法:选取我院e抗原阳性CHB患者200例(2014年5月至2019年6月),常规治疗基础上,采用恩替卡韦治疗的98例为对照组,在对照组基础上采用聚乙二醇干扰素α-2b注射液治疗的102例为观察组。比较两组乙肝e抗原(HBeAg)转阴率,乙肝病毒定量(HBV-DNA)转阴率,丙氨酸转氨酶(ALT)复常率,治疗前、治疗6个月后肝功能[天冬氨酸转氨酶(AST)、ALT],不良反应发生率。结果:观察组HBeAg转阴率、HBV-DNA转阴率、ALT复常率71.57%、75.49%、75.49%高于对照组41.84%、32.65%、45.92%(P<0.05),两组不良反应发生率比较无明显差异(P>0.05);治疗6个月后,观察组AST、ALT水平低于对照组(P<0.05)。结论:聚乙二醇干扰素α-2b注射液联合恩替卡韦治疗e抗原阳性CHB患者,可有效地抑制病毒复制,改善肝功能,且安全性高。
Objective:To investigate the clinical efficacy of pegylated interferonα-2b injection combined with entecavir in patients with e antigen positive chronic hepatitis B(CHB).Methods:200 cases of CHB patients with positive e antigen in our hospital(may 2014 to June 2019)were selected.On the basis of conventional treatment,98 cases were treated with entecavir as the control group,and 102 cases were treated with pegylated interferonα-2b injection on the basis of the control group.The negative conversion rate of hepatitis B e antigen(HBeAg),the negative rate of hepatitis B virus quantitative(HBV-DNA),the normalization rate of alanine aminotransferase(ALT),liver function[aspartate aminotransferase(AST),ALT]and the incidence of adverse reactions were compared between the two groups.Results:The HBeAg negative rate,HBV-DNA negative conversion rate and ALT normalization rate in the observation group were 71.57%,75.49%and 75.49%higher than those in the control group(41.84%,32.65%and 45.92%,P<0.05),and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05);after 6 months of treatment,the levels of AST and ALT in the observation group were lower than those in the control group(P<0.05).Conclusion:Pegylated interferonα-2b injection combined with entecavir in the treatment of e antigen positive CHB patients can effectively inhibit virus replication,improve liver function,and has high safety.
作者
许光锋
XU Guang-feng(Department of Infection,People's Hospital ofXiayi County,Xiayi Henan 476400,China)
出处
《药品评价》
CAS
2020年第11期33-35,共3页
Drug Evaluation
